A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

NCT01850602 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemodialysis
Hyperphosphatemia

Interventions

DRUG: PA21
DRUG: Sevelamer hydrochloride

Sponsor

Kissei Pharmaceutical Co., Ltd.